Lamera (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil blocks the AT1 receptors that normally bind angiotensin II, a hormone that narrows blood vessels and stimulates aldosterone release. Inhibiting this pathway prevents vasoconstriction and fluid retention, contributing to a reduction in systemic blood pressure.

The appropriate dose of Lamera is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Lamera is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit outweighs the risk. Both olmesartan and amlodipine cross the placenta and may affect the fetus, so a healthcare professional should evaluate alternatives.

To place an order, submit an enquiry on the Lamera product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Compared with single‑agent therapy, Lamera offers the convenience of a fixed‑dose combination, potentially improving adherence. It provides additive blood‑pressure reduction without the need for separate prescriptions, whereas alternatives may require multiple pills or different drug classes to achieve similar control.

Lamera tablets should be stored at ambient temperature, below 25 °C, in their original blister pack or container. Protect the product from excess moisture and direct sunlight to maintain stability throughout its shelf life.

Lamera is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically advised.

Serious risks include angio‑edema, severe hypotension, hyperkalemia, and significant renal impairment. Patients should seek immediate medical attention if they experience swelling of the face or throat, faintness, rapid heartbeat, or sudden changes in urine output.

Lamera is contraindicated in patients with known hypersensitivity to olmesartan, amlodipine, or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment, uncontrolled heart failure, or a history of angio‑edema related to ARB or calcium‑channel blocker therapy.